Jasplakinolide
(Synonyms: NSC 613009) 目录号 : GC17312A binder and modulator of F-actin
Cas No.:102396-24-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Jasplakinolide is a natural macrocyclic peptide first isolated from a marine sponge. It potently inhibits the proliferation of PC3 prostate carcinoma cells (IC50 = 35 nM) by binding F-actin (KD = 15 nM).[1] This binding of jasplakinolide to actin, which is competitive with phalloidin, stabilizes actin filaments in vitro but disrupts actin filaments and induces irregular polymerization of monomeric actin in vivo.[1],[2] This compound is used to investigate the role of actin in diverse cellular roles, such as motility, transport, and development.[3],[4]
Reference:
[1]. Bubb, M.R., Senderowicz, A.M.J., Sausville, E.A., et al. Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. The Journal of Biological Chemisty 269(21), 14869-14871 (1994).
[2]. Bubb, M.R., Spector, I., Beyer, B.B., et al. Effects of jasplakinolide on the kinetics of actin polymerization. An explanation for certain in vivo observations. The Journal of Biological Chemisty 275(7), 5163-5170 (2000).
[3]. Van Goor, D., Hyland, C., Schaefer, A.W., et al. The role of actin turnover in retrograde actin network flow in neuronal growth cones. PLoS One 7(2), (2012).
[4]. Zhang, X., Cui, X., Cheng, L., et al. Actin stabilization by jasplakinolide affects the function of bone marrow-derived late endothelial progenitor cells. PLoS One 7(11), (2012).
| Cas No. | 102396-24-7 | SDF | |
| 别名 | NSC 613009 | ||
| 化学名 | (4R,7R,10S,13R,17R,19S,E)-7-((2-bromo-1H-indol-3-yl)methyl)-4-(4-hydroxyphenyl)-8,10,13,15,17,19-hexamethyl-1-oxa-5,8,11-triazacyclononadec-15-ene-2,6,9,12-tetraone | ||
| Canonical SMILES | BrC(NC1=CC=CC=C21)=C2C[C@H](C(N[C@@H](C(C=C3)=CC=C3O)CC(O[C@@H](C)C[C@@H](C)C=C(C)C[C@@H](C)C(N[C@H]4C)=O)=O)=O)N(C)C4=O | ||
| 分子式 | C36H45BrN4O6 | 分子量 | 709.67 |
| 溶解度 | Soluble in ethanol, methanol and DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4091 mL | 7.0455 mL | 14.0911 mL |
| 5 mM | 0.2818 mL | 1.4091 mL | 2.8182 mL |
| 10 mM | 0.1409 mL | 0.7046 mL | 1.4091 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。